What is Concure Oncology?
Concure Oncology operates at the intersection of medical technology and oncology, focusing specifically on the development of innovative devices for early-stage breast cancer treatment. Its flagship offering, the Breast Microseed Treatment (BMT), represents a sophisticated integration of medical hardware, proprietary protocols, and specialized equipment. By enabling medical partners to perform precise, localized radiation therapy following lumpectomy procedures, Concure Oncology addresses a vital gap in patient care, prioritizing both clinical efficacy and procedural efficiency.
The company's market position is defined by its commitment to evidence-based oncology solutions. By providing the necessary tools and training for BMT, Concure Oncology empowers healthcare providers to deliver targeted treatment that minimizes systemic exposure while maximizing therapeutic outcomes. This specialized focus has established the firm as a key player in the medical device sector, particularly within the niche of breast cancer management.
How much funding has Concure Oncology raised?
Concure Oncology has raised a total of $7.6M across 6 funding rounds:
Debt
$500K
Debt
$1.7M
Debt
$825K
Multiple Rounds
$4.7M
Debt (2015): $500K, investors not publicly disclosed
Debt (2016): $1.7M, investors not publicly disclosed
Debt (2017): $825K, investors not publicly disclosed
Private Equity (2020): $2.5M featuring Undisclosed
Debt (2020): $150K backed by PPP
Unspecified (2020): $2M, investors not publicly disclosed
Key Investors in Concure Oncology
Undisclosed Investors
PPP
Public-Private Partnership
Undisclosed Investors
What's next for Concure Oncology?
With the recent strategic investment, Concure Oncology is well-positioned to accelerate its commercialization efforts and broaden the adoption of its BMT procedure across major healthcare networks. The company's forward-looking strategy likely involves scaling its operational capacity to meet the rising demand for minimally invasive, high-precision oncology interventions. Furthermore, the firm is expected to leverage this capital to refine its technological suite, potentially exploring new applications for its radiation delivery platform.
As the company moves beyond its initial development and scaling phases, the focus will shift toward long-term clinical validation and market penetration. By strengthening its partnerships with oncology centers and investing in ongoing research, Concure Oncology aims to solidify its status as a leader in the oncology medical device market, ultimately improving the standard of care for patients undergoing early-stage breast cancer treatment.
